All News
Anti-Sclerostin Drug Hampered by Heart Problems
Reuters reports that FDA approval of romosozumab (brand name Evenity) may be held up because of higher rates of cardiac events seen in a late-stage clinical trial.
Read Article
The RheumNow Week in Review – 17 May 2017
Dr. Jack Cush reviews highlights and updates from the past week on RheumNow.com:
Read Article
Inflammatory Arthritis Stable after Switch to Biosimilar Infliximab
The DANBIO registrys has demonstrated that switching from infliximab (Remicade) to biosimilar CT-P13 (Inflectra in the U.S., Remsima in Europe) does not appear to have any negative effect on inflammatory arthritis disease activity, Danish researchers reported.
Read Article
Educational Intervention Facilitates Treat-to-Target Management in Rheumatoid Arthritis
Treat-to-target education through group-based quality improvement sessions can result in wider use of treat-to-target in practice, according to researchers.
Read Article
NOR-SWITCH Study Validates Biosimilar Use in Multiple Indications
Lancet reports the results of the NOR-SWITCH study - a trial performed in Norway as biosimilars were being introduced.
Read Article
Rituximab May Benefit Rheumatoid Lung
A retrospective study shows that rituximab treatment of RA-related interstitial lung disease may improve or forestall ILD progression.
Read Article
The RheumNow Week in Review – 12 May 2017
Dr. Jack Cush highlights the big stories, news and articles from this week at RheumNow.com.
Read Article
ACP Guideline Recommends Generic Bisphosphonates But Limits DEXA Use
The American College of Physicians (ACP) has updated its 2008 clincial practice guideline on the treatment of low bone density and osteoporosis to prevent fractures in men and women. The new guideline is in favor of generic bisphosphonate use and recommends against using menopausal estrogen therapy and against DEXA monitoring during the first 5 years.
Read Article
Calcium Supplements and Cardiovascular Risk
Dr. Nancy Lane answers questions about the intake of Calcium, Vitamin D and the cardiovascular risk of supplemental calcium.
Read Article
Increased Comorbidities in Rheumatoid Arthritis
A population based study from Taiwan examined the frequencies of comorbidities in a rheumatoid arthritis (RA) population.
Read Article
Enthesitis-Related Arthritis in Children
Enthesitis-related arthritis (ERA) is an emerging subset of juvenile idiopathic arthritis (JIA) recognized for its distinctive clinical characteristics.
Read Article
NEJM: Adalimumab and MTX Effective in JIA Uveitis
The NEJM has published the results of a randomized, placebo-controlled trial showing adalimumab and methotrexate is effective in reducing ocular flares in juvenile idiopathic arthritis with uveitis.
Read Article
FDA Approves Abaloparatide for High Risk Patients
The FDA has approved injectable Tymlos (abaloparatide) for use in postmenopausal osteoporosis patients at high risk for fracture, as the drug has been shown to reduce the risk of vertebral and nonvertebral fractures in such patients.
Read Article
Best to Rehab at Home Following Joint Replacement
A New York Times article sheds light on recent evidence suggesting that those undergoing hip or knee replacement will do just as well with home therapy compared to inpatient rehabilitation following surgery.
Read Article
Pregnancy Flares in RA and Spondylitis
Despite the folklore, not all women with arthritis who become pregnant will improve or go into remission. Recent studies have suggested that up to one-third of RA patients will flare during pregnancy.
Read Article
Consensus on OP Drug Holidays
Extending bisphosphonate treatment beyond 3–5 years does not confer additional benefit in low-risk populations. Treatment re-initiation (usually 1–3 years after bisphosphonate withdrawal) depends on risk factors, new fractures and bone mineral density. The evidence regarding denosumab discontinuation is limited but caution is advised, as there may be a “rebound effect” with regard to fractures.
Read Article
FDA Approves Renflexis as Second Infliximab Biosimilar
On the 21st of April, the FDA approved another infliximab biosimilar, called Renflexis (Infliximab-abda) following on the biologics license application of the South Korean manufacturer Samsung Bioepis Co. LTD. In early developmental trials this agent was also called SB2.
Read Article
The RheumNow Week in Review – 21 April 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.com:
Read Article
Paradoxical Toxicities with TNF Inhibitors
Something is curiously wrong when a drug induces the disease it is intended to treat. Yet this phenomenon has been described with all five FDA-approved TNF inhibitors.
Read Article
FDA Delays Baricitinib Decision
Eli Lilly and Company and Incyte Corporation announced today that the U.S. Food and Drug Administration (FDA) has delayed its' decision on baricitinib by issuing a complete response letter for baricitinib's New Drug Application.
Read Article